Skip to main content

Table 1 Demographic and clinical characteristics of rheumatoid arthritis patients treated with rituximab

From: Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

Age (years) 62 (1.8)
Female (%) 61
Disease duration (years) 15 (2.8)
Previous therapies  
   Number of disease-modifying anti-rheumatic drugs used 2.6 (1 to 5)
   Number of biologic agents used 1.6 (0 to 3)
Baseline disease characteristics  
   Rheumatoid factor-positive (%) 52
   Disease activity score of 28 joint counts 6.3 (0.2)
   Swollen joints (28 joints) 9.3 (1.1)
   Tender joints (28 joints) 12.8 (1.3)
   Patient's pain assessment 69.7 (2.9)
   Patient's global assessment 67.3 (3.3)
   Physician's global assessment 54.8 (3.4)
   Health Assessment Questionnaire 0.9 (0.09)
   Erythrocyte sedimentation rate (mm/hour) 51 (6.1)
   Hemoglobin (g/dl) 12.9 (0.4)
Concomitant disease-modifying anti-rheumatic drugs  
   Methotrexate  
Patients (%) 68
Dose (mg/week) 16.3 (7.5 to 25)
   Leflunomide  
Patients (%) 29
Dose (mg/day) 17 (10 to 20)
   Glucocorticoids  
Patients (%) 29
Dose (mg/day) 5.5 (5 to 10)
   Rituximab monotherapy 3
  1. Data expressed as mean (standard error of the mean), percentage, or mean (range); n = 31.